Repare Therapeutics Inc. shareholders have approved the acquisition by XenoTherapeutics, Inc. and Xeno Acquisition Corp.
The special resolution approving the Arrangement was supported by a high percentage of votes cast by shareholders.
The Arrangement is subject to the approval of the Superior Court of Québec and other customary closing conditions.
Approved Acquisition
Shareholders approved the acquisition of all issued and outstanding common shares by XenoTherapeutics, Inc.
Special Resolution
The special resolution regarding the Arrangement was approved by a significant percentage of shareholder votes.
Arrangement Conditions
The completion of the Arrangement is expected around January 28, 2026, subject to Court approval and other closing conditions.
- Repare Therapeutics focuses on precision oncology using a synthetic lethality approach.
- XenoTherapeutics is a research foundation dedicated to advancing xenotransplantation through scientific research.
- The forward-looking statements in the news release highlight the anticipated outcomes of the Transaction.
The approval of the acquisition marks a significant step for Repare Therapeutics, shaping its future in the precision oncology sector.